Arcus Biosciences (RCUS) news

PTC Industries - Raises 18 bln rupees through qualified institutions placement

PTC Industries has raised ₹18 billion through a qualified institutional placement (QIP), a move aimed at strengthening its capital base and supporting ongoing expansion initiatives. The placement was oversubscribed, reflecting strong investor confidence in the company’s strategic direction and…

Aequs signs long-term supply pacts with Safran

Standard Chartered PLC - Standard Chartered launches RLUSD custody and joins planned collateral integration with Ripple and Lmax Group

Standard Chartered PLC has announced the launch of custody services for Ripple USD (RLUSD), a stablecoin backed by U.S. dollars and designed for institutional use. This move aligns with the bank’s broader strategy to expand its digital asset offerings and support the integration of traditional…

Arcus Biosciences, Inc.: TD Cowen initiates coverage with buy rating

TD Cowen has initiated coverage on Arcus Biosciences, Inc. (NYSE: RCUS) with a "Buy" rating, signaling positive outlook on the biotechnology company. The move comes amid ongoing developments involving the company, which recently received undisclosed regulatory or corporate news. Arcus Biosciences,…

Arcus Biosciences, Inc.: Truist Securities raises target price to $40 from $35

Truist Securities has revised its price target for Arcus Biosciences, Inc. (NASDAQ: RCUS), raising it to $40 from $35, reflecting updated expectations for the biotechnology company’s near-term prospects. The adjustment follows recent developments in Arcus’ clinical pipeline and evolving market…